An amplification assay for the measurement of alkaline phosphatase has been combined with a luminescent end point using the luminol-peroxidase system to produce the first enzyme-amplified chemiluminescent assay based on the principle of prosthetogenesis. This assay is both quantitative and extremely
Chemiluminescent determination of leukocyte alkaline phosphatase: an advantageous alternative to the cytochemical assay
✍ Scribed by Marília P.P. Kanegae; Valdecir F. Ximenes; Roberto P. Falcão; Virgílio A.R. Colturato; Éderson R. de Mattos; Iguatemy L. Brunetti; Luiz Marcos da Fonseca
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 134 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The determination of leukocyte alkaline phosphatase (LAP) is used as an aid to diagnose many diseases in the laboratory. For example, it can be used to distinguish chronic myeloid leukemia (CML) from other myeloproliferative disorders (particularly myelofibrosis and polycythemia) and leukemoid reactions (LR). Traditionally, this test is performed with the use of subjective cytochemical assays that assign a score to the level of LAP. Here we present a nonsubjective, quantitative, sensitive, and inexpensive chemiluminescent technique that determines LAP based on the commercial reagent Immulite^®^ (AMPPD). To validate this methodology, intact leukocytes obtained from 32 healthy subjects, nine CML patients, and nine LR patients were submitted to the optimized protocol. By measuring the light emission elicited by four concentrations of neutrophils, we were able to estimate the activity of LAP per cell (the slope of the curve obtained by linear regression). A high linear correlation was found between the chemiluminescent result (slope) and the cytochemical score. The slope for healthy individuals ranged between 0.61 and 8.49 (10^–5^ mV.s/cell), with a median of 2.04 (10^–5^ mV.s/cell). These results were statistically different from those of CML patients (range=0.07–1.75, median=0.79) and LR patients (range= 3.84–47.24, median=9.58; P<0.05). J. Clin. Lab. Anal. 21:91–96, 2007. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES